Go Pro

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Vaxcyte, Inc. stock logo
PCVX
Vaxcyte
$54.66
-1.8%
$52.57
$29.08
$65.00
$7.89B1.221.56 million shs1.12 million shs
Qiagen N.V. stock logo
QGEN
Qiagen
$41.38
-0.2%
$38.12
$32.53
$57.81
$8.53B0.643.02 million shs1.84 million shs
Repligen Corporation stock logo
RGEN
Repligen
$131.96
-4.1%
$131.68
$100.99
$175.77
$7.44B1.061.13 million shs1.36 million shs
Bio-Techne Corp stock logo
TECH
Bio-Techne
$71.60
-0.2%
$60.48
$43.19
$72.16
$11.21B1.295.79 million shs2.07 million shs
10 Best Stocks to Own - Summer 2026 Cover

Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Summer 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Vaxcyte, Inc. stock logo
PCVX
Vaxcyte
0.00%-2.74%+1.83%-8.12%+49.92%
Qiagen N.V. stock logo
QGEN
Qiagen
0.00%+0.46%+6.24%+7.79%-22.02%
Repligen Corporation stock logo
RGEN
Repligen
0.00%-10.38%-9.14%+12.21%+12.66%
Bio-Techne Corp stock logo
TECH
Bio-Techne
0.00%-0.72%+1.27%+32.17%+29.45%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Vaxcyte, Inc. stock logo
PCVX
Vaxcyte
$54.66
-1.8%
$52.57
$29.08
$65.00
$7.89B1.221.56 million shs1.12 million shs
Qiagen N.V. stock logo
QGEN
Qiagen
$41.38
-0.2%
$38.12
$32.53
$57.81
$8.53B0.643.02 million shs1.84 million shs
Repligen Corporation stock logo
RGEN
Repligen
$131.96
-4.1%
$131.68
$100.99
$175.77
$7.44B1.061.13 million shs1.36 million shs
Bio-Techne Corp stock logo
TECH
Bio-Techne
$71.60
-0.2%
$60.48
$43.19
$72.16
$11.21B1.295.79 million shs2.07 million shs
10 Best Stocks to Own - Summer 2026 Cover

Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Summer 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Vaxcyte, Inc. stock logo
PCVX
Vaxcyte
0.00%-2.74%+1.83%-8.12%+49.92%
Qiagen N.V. stock logo
QGEN
Qiagen
0.00%+0.46%+6.24%+7.79%-22.02%
Repligen Corporation stock logo
RGEN
Repligen
0.00%-10.38%-9.14%+12.21%+12.66%
Bio-Techne Corp stock logo
TECH
Bio-Techne
0.00%-0.72%+1.27%+32.17%+29.45%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Vaxcyte, Inc. stock logo
PCVX
Vaxcyte
2.44
Hold$86.0057.34% Upside
Qiagen N.V. stock logo
QGEN
Qiagen
2.36
Hold$43.344.75% Upside
Repligen Corporation stock logo
RGEN
Repligen
2.88
Moderate Buy$165.3625.31% Upside
Bio-Techne Corp stock logo
TECH
Bio-Techne
2.12
Hold$68.08-4.92% Downside

Current Analyst Ratings Breakdown

Latest QGEN, TECH, RGEN, and PCVX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/15/2026
Qiagen N.V. stock logo
QGEN
Qiagen
Reiterated RatingHold
7/14/2026
Repligen Corporation stock logo
RGEN
Repligen
UpgradeSell (D)Sell (D+)
7/14/2026
Qiagen N.V. stock logo
QGEN
Qiagen
Set Price TargetBuyHold$45.50
7/14/2026
Vaxcyte, Inc. stock logo
PCVX
Vaxcyte
DowngradeHoldStrong Sell
7/9/2026
Bio-Techne Corp stock logo
TECH
Bio-Techne
DowngradeOutperformSector Perform$62.00 ➝ $73.00
7/7/2026
Repligen Corporation stock logo
RGEN
Repligen
UpgradeBuy
7/7/2026
Repligen Corporation stock logo
RGEN
Repligen
UpgradeHoldBuy$185.00
7/6/2026
Vaxcyte, Inc. stock logo
PCVX
Vaxcyte
Reiterated RatingSell (D-)
7/6/2026
Repligen Corporation stock logo
RGEN
Repligen
Reiterated RatingOutperform$160.00
7/6/2026
Bio-Techne Corp stock logo
TECH
Bio-Techne
DowngradeStrong-BuyHold
6/30/2026
Bio-Techne Corp stock logo
TECH
Bio-Techne
DowngradeBuyHold
(Data available from 7/26/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Vaxcyte, Inc. stock logo
PCVX
Vaxcyte
N/AN/AN/AN/A$20.51 per shareN/A
Qiagen N.V. stock logo
QGEN
Qiagen
$2.09B4.08$3.41 per share12.15$17.89 per share2.31
Repligen Corporation stock logo
RGEN
Repligen
$738.26M10.08$3.42 per share38.62$37.42 per share3.53
Bio-Techne Corp stock logo
TECH
Bio-Techne
$1.22B9.19$2.44 per share29.29$12.24 per share5.85
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Vaxcyte, Inc. stock logo
PCVX
Vaxcyte
-$766.63M-$6.88N/AN/AN/AN/A-32.51%-29.51%8/5/2026 (Estimated)
Qiagen N.V. stock logo
QGEN
Qiagen
$424.88M$1.9121.6115.794.1319.16%14.40%8.40%8/5/2026 (Confirmed)
Repligen Corporation stock logo
RGEN
Repligen
$48.89M$0.90146.6254.302.546.73%4.88%3.48%7/28/2026 (Estimated)
Bio-Techne Corp stock logo
TECH
Bio-Techne
$73.40M$0.69103.7740.688.539.05%13.57%10.66%8/5/2026 (Estimated)

Latest QGEN, TECH, RGEN, and PCVX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/5/2026Q2 2026
Vaxcyte, Inc. stock logo
PCVX
Vaxcyte
-$2.0556N/AN/AN/A$12.50 millionN/A
8/5/2026Q2 2026
Qiagen N.V. stock logo
QGEN
Qiagen
$0.60N/AN/AN/A$527.65 millionN/A
8/5/2026Q4 2026
Bio-Techne Corp stock logo
TECH
Bio-Techne
$0.52N/AN/AN/A$314.65 millionN/A
7/28/2026Q2 2026
Repligen Corporation stock logo
RGEN
Repligen
$0.46N/AN/AN/A$201.59 millionN/A
5/7/2026Q1 2026
Qiagen N.V. stock logo
QGEN
Qiagen
$0.54$0.54N/A$0.33$496.15 million$492.32 million
5/6/2026Q1 2026
Vaxcyte, Inc. stock logo
PCVX
Vaxcyte
-$1.7411-$2.30-$0.5589-$2.30$12.50 millionN/A
5/6/2026Q3 2026
Bio-Techne Corp stock logo
TECH
Bio-Techne
$0.55$0.53-$0.02$0.32$316.11 million$311.42 million
5/5/2026Q1 2026
Repligen Corporation stock logo
RGEN
Repligen
$0.38$0.48+$0.10$0.15$192.05 million$194.26 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Vaxcyte, Inc. stock logo
PCVX
Vaxcyte
N/AN/AN/AN/AN/A
Qiagen N.V. stock logo
QGEN
Qiagen
$0.350.85%N/A18.32%N/A
Repligen Corporation stock logo
RGEN
Repligen
N/AN/AN/AN/AN/A
Bio-Techne Corp stock logo
TECH
Bio-Techne
$0.320.45%N/A46.38%N/A

Latest QGEN, RGEN, TECH, and PCVX Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
5/11/2026
Qiagen N.V. stock logo
QGEN
Qiagen
annual$0.350.9%7/7/20267/7/20267/14/2026
5/6/2026
Bio-Techne Corp stock logo
TECH
Bio-Techne
quarterly$0.080.72%5/18/20265/18/20265/29/2026
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Vaxcyte, Inc. stock logo
PCVX
Vaxcyte
N/A
7.49
7.49
Qiagen N.V. stock logo
QGEN
Qiagen
0.49
3.21
2.57
Repligen Corporation stock logo
RGEN
Repligen
0.26
9.20
7.78
Bio-Techne Corp stock logo
TECH
Bio-Techne
0.10
4.49
3.18

Institutional Ownership

CompanyInstitutional Ownership
Vaxcyte, Inc. stock logo
PCVX
Vaxcyte
96.78%
Qiagen N.V. stock logo
QGEN
Qiagen
70.00%
Repligen Corporation stock logo
RGEN
Repligen
97.64%
Bio-Techne Corp stock logo
TECH
Bio-Techne
98.95%

Insider Ownership

CompanyInsider Ownership
Vaxcyte, Inc. stock logo
PCVX
Vaxcyte
3.30%
Qiagen N.V. stock logo
QGEN
Qiagen
9.00%
Repligen Corporation stock logo
RGEN
Repligen
0.60%
Bio-Techne Corp stock logo
TECH
Bio-Techne
1.30%
CompanyEmployeesShares OutstandingFree FloatOptionable
Vaxcyte, Inc. stock logo
PCVX
Vaxcyte
160144.40 million139.63 millionOptionable
Qiagen N.V. stock logo
QGEN
Qiagen
5,654206.07 million187.53 millionOptionable
Repligen Corporation stock logo
RGEN
Repligen
2,00056.41 million56.07 millionOptionable
Bio-Techne Corp stock logo
TECH
Bio-Techne
3,100156.57 million154.53 millionOptionable

Recent News About These Companies

Bio-Techne Corporation

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Vaxcyte stock logo

Vaxcyte NASDAQ:PCVX

$54.66 -0.98 (-1.76%)
Closing price 07/24/2026 04:00 PM Eastern
Extended Trading
$54.62 -0.04 (-0.08%)
As of 07/24/2026 07:34 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California.

Qiagen stock logo

Qiagen NYSE:QGEN

$41.38 -0.07 (-0.18%)
Closing price 07/24/2026 03:59 PM Eastern
Extended Trading
$41.52 +0.14 (+0.34%)
As of 07/24/2026 07:34 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials. The firm assay technologies make these biomolecules visible and ready for analysis. Its bioinformatics software and knowledge bases interpret data to report relevant, actionable insights. The company was founded by Detlev H. Riesner and Metin Colpan on April 29, 1996, and is headquartered in Venlo, the Netherlands.

Repligen stock logo

Repligen NASDAQ:RGEN

$131.96 -5.64 (-4.10%)
Closing price 07/24/2026 04:00 PM Eastern
Extended Trading
$132.06 +0.09 (+0.07%)
As of 07/24/2026 07:34 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products. The company's chromatography products include OPUS pre-packed chromatography columns, which are used in the purification of biologics; and OPUS smaller-scale columns that are used in the high throughput process development screening, viral clearance validation studies, and scale down validation of chromatography processes. It also offers ELISA test kits; and chromatography resins under the CaptivA brand. In addition, the company provides filtration products, such as XCell Alternating Tangential Flow systems that are filtration devices used in upstream perfusion and cell culture processing; TangenX flat sheet cassettes, which are used in downstream biologic drug concentration, buffer exchange, and formulation processes; KrosFlo tangential flow filtration and tangential flow depth filtration systems; Spectra/Por laboratory and process dialysis products, and ProConnex TFDF flow paths. Further, it provides process analytics products, such as slope spectroscopy systems under the SoloVPE, FlowVPE, and FlowVPX brands. The company sells its products to life sciences, biopharmaceutical, and diagnostics companies; laboratory researchers; and contract manufacturing organizations. Repligen Corporation has collaboration agreements with Navigo Proteins GmbH to develop multiple affinity ligands. The company was incorporated in 1981 and is headquartered in Waltham, Massachusetts.

Bio-Techne stock logo

Bio-Techne NASDAQ:TECH

$71.60 -0.17 (-0.24%)
Closing price 07/24/2026 04:00 PM Eastern
Extended Trading
$71.30 -0.30 (-0.43%)
As of 07/24/2026 07:34 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research and clinical diagnostic markets in the United States, the United Kingdom, rest of Europe, Middle East, and Africa, Greater China, rest of Asia-Pacific, and internationally. The company operates through two segments, Protein Sciences, and Diagnostics and Genomics. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was incorporated in 1976 and is headquartered in Minneapolis, Minnesota.